Pfizer Inc. has chosen to donate the rights of its royalties from the sale of Bavencio (avelumab) in the United States to the American Association for Cancer Research.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
